Browse by author
Lookup NU author(s): Emeritus Professor Paul Corris
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
© 2024. In Riociguat rEplacing PDE5i therapy evaLuated Against Continued PDE5i thErapy (REPLACE) (NCT02891850), improvements in risk status were observed in patients with pulmonary arterial hypertension (PAH) at intermediate risk switching to riociguat versus continuing phosphodiesterase-5 inhibitors (PDE5i). This post hoc study applied the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2 and Comparative Prospective Registry of Newly Initiated Therapies for Pulmonary (COMPERA) 2.0 risk-assessment tools to REPLACE to investigate the impact of baseline risk status on clinical improvement. The proportions of riociguat- and PDE5i-treated patients achieving the primary end-point at REVEAL Lite 2 low, intermediate, and high baseline risk reflected the overall population. Proportions of riociguat-treated patients achieving the primary end-point were comparable between the COMPERA 2.0 intermediate-low risk (39%) and intermediate-high risk (43%) groups. Our findings show that patients in REPLACE achieved clinical improvement by switching from PDE5i to riociguat across all COMPERA 2.0 and most REVEAL Lite 2 baseline risk strata.
Author(s): Benza RL, Simonneau G, Ghofrani H-A, Corris PA, Langleben D, Rosenkranz S, White RJ, Cheng C-C, Campos FTAF, Kim H-K, Souza R, Chang M, Rahner C, Meier C, Hoeper MM
Publication type: Article
Publication status: Published
Journal: Journal of Heart and Lung Transplantation
Year: 2024
Volume: 43
Issue: 10
Pages: 1756-1760
Print publication date: 01/10/2024
Online publication date: 07/06/2024
Acceptance date: 02/04/2018
Date deposited: 16/07/2024
ISSN (print): 1053-2498
ISSN (electronic): 1557-3117
Publisher: Elsevier Inc.
URL: https://doi.org/10.1016/j.healun.2024.06.002
DOI: 10.1016/j.healun.2024.06.002
PubMed id: 38852934
Altmetrics provided by Altmetric
